On December 10th 2015 Algiax got its approval from the German authorities (BfArM) to start the Phase Ib study entitled “Pharmacodynamic Effects of AP-325 in Healthy Male Subjects using the Intradermal (ID) Capsaicin and Pressure Pain Models”.
On December 10th 2015 Algiax got its approval from the German authorities (BfArM) to start the Phase Ib study entitled “Pharmacodynamic Effects of AP-325 in Healthy Male Subjects using the Intradermal (ID) Capsaicin and Pressure Pain Models”.
Use of SalesViewer® technology:
This website uses SalesViewer® technology from SalesViewer® GmbH on the basis of the website operator’s legitimate interests (Section 6 paragraph 1 lit.f GDPR) in order to collect and save data on marketing, market research and optimisation purposes.
In order to do this, a javascript based code, which serves to capture company-related data and according website usage. The data captured using this technology are encrypted in a non-retrievable one-way function (so-called hashing). The data is immediately pseudonymised and is not used to identify website visitors personally
The data stored by Salesviewer will be deleted as soon as they are no longer required for their intended purpose and there are no legal obligations to retain them.
The data recording and storage can be repealed at any time with immediate effect for the future, by clicking on https://www.salesviewer.com/opt-out in order to prevent SalesViewer® from recording your data. In this case, an opt-out cookie for this website is saved on your device. If you delete the cookies in the browser, you will need to click on this link again.